A Phase IIA, multicentre, open study on the safety and efficacy of allogeneic osteoblastic cells (ALLOB) implantation in multiple non-infected delayed-union (DU) fractures

Trial Profile

A Phase IIA, multicentre, open study on the safety and efficacy of allogeneic osteoblastic cells (ALLOB) implantation in multiple non-infected delayed-union (DU) fractures

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2017

At a glance

  • Drugs Allogeneic osteoblastic cell therapy Bone Therapeutics (Primary)
  • Indications Fracture
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bone Therapeutics
  • Most Recent Events

    • 22 Sep 2017 Status changed from recruiting to completed.
    • 31 Aug 2017 According to Bone Therapeutics media release, the company expects to announce interim results from this study in Sep 2017.
    • 19 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top